Ann Thorac Surg 2008;85:S792-S796. doi:10.1016/j.athoracsur.2007.11.051
© 2008 The Society of Thoracic Surgeons
Supplement: The Minimally Invasive Thoracic Surgery Summit
Airway Stents
Cynthia S. Chin, MD*,
Virginia Litle, MD,
Jaime Yun, MD,
Todd Weiser, MD,
Scott J. Swanson, MD
Department of Cardiothoracic Surgery, Mount Sinai Medical Center, New York, New York
* Address correspondence to Dr Chin, 1190 Fifth Ave, Box 1028 GP2W, New York, NY 10029 (Email: cynthia.chin{at}mountsinai.org).
Presented at the Minimally Invasive Thoracic Surgery Summit, New York, NY, June 8–9, 2007.
 |
Abstract
|
|---|
Airway stenting has been well used in the treatment and palliation of patients with malignant stenoses and to a lesser extent in those with benign disease causing airway compromise. Stents are either constructed of silicone or metal, usually a nitinol, a nickel and titanium alloy. The different categories of stents have positive and negative attributes that play a role in choosing the proper stent. This article aims to discuss these issues with regards to malignant and benign tracheobronchial disease.
 |
Introduction
|
|---|
The National Cancer Institute projects there will be 213,380 new cases of lung cancer this year [1]. Surgery is the treatment of choice for those patients with early-stage lung cancers; unfortunately, most patients will have advanced lung cancer at the time of diagnosis. These patients branded with a poor prognosis may not benefit from surgery with a curative intent; however, they will require procedures for palliation with the hopes of providing a reasonable quality of life. It has been reported that in up to 30% of patients with lung cancer, central airway obstruction will develop that may be secondary to endoluminal disease or external compression by a hilar tumor or bulky lymphadenopathy [2–5]. In these patients it becomes imperative that palliative therapy be considered for symptomatic relief and improvement of quality of life.
Strictures and critical stenoses may result from benign causes such as postintubation or posttracheostomy endothelial trauma, Wegner granulomatosis, or tuberculosis. For benign disease amenable to surgery, resection and reconstruction is the gold standard of therapy; however, for those patients who are not surgical candidates because of disease or existing comorbidities, endoscopic therapies are needed.
 |
Indications for Stent Placement
|
|---|
Malignant central airway compression produces dyspnea, stridor, hemorrhage, or obstructive pneumonia, or a combination. Indications for use of stents in this disease include but are not limited to the list in Table 1. The only definitive contraindication for placement of an airway stent is when there is external compression of the airway by a vessel. Patients in whom these stents were placed had an unacceptably high rate of erosion, hemorrhage, and death [6]. Although other palliative options will not be discussed in detail, the use of several interventions in conjunction with stents cannot be over emphasized [6–10].
Brutsche and colleagues [11] recently reported the outcomes of treated advanced non-small cell lung cancer with and without airway obstruction. They studied 144 patients with advanced disease who were receiving palliative chemotherapy to see if central airway obstruction was a negative prognostic factor. The patients with obstruction had treatments with laser alone (25%), stent alone (25%), or both (50%). Median survival was 8.4 months (range, 4.8 to 17.1 months) in the patients without airway obstruction and 8.2 months (range, 3.7 to 17.9 months) in those with central airway obstruction, which was not a significant difference (p = 0.395). Airway compression does not appear to be a poor prognostic sign in these patients, but they may benefit from stenting of the obstruction to improve their quality of life.
Benign strictures secondary to inflammatory and infectious disease may need to be stented if the patients disease process or comorbidities prohibit definitive surgical repair. Another group of patients who may benefit from placement of endobronchial stents are lung transplant recipients. Airway dehiscence develops in a small percentage of these patients in the immediate perioperative period, or stricture develops weeks to months after transplantation. These complications have been attributed to bronchial blood supply of the donor lung, perioperative infection, and immunosuppression. Airway complications drastically improved in the early years of lung transplantation; however, the incidence of such complication in the last decade has not changed greatly and endobronchial therapies are still required [12].
An endobronchial prosthesis needs to fulfill many requirements to be considered ideal. An airway stent for palliation should, most importantly, reestablish the airway with minimal morbidity and mortality. Table 2
lists the characteristics of an ideal stent; however, such a stent is not in existence.
 |
Types of Stents
|
|---|
Many types of stents are available from many different manufacturers. In general, they can be classified into one of four categories (Table 3). Most modern day silicone stents are derived from the Montgomery T tube, which was originally described in the 1960s [13]. The Montgomery T tube has a side arm that requires a tracheostomy. The silicone stents inhibited mucociliary mechanisms that clear the airway of secretions. Dumon developed a silicone stent with studs on the outer wall to decrease impairment of cilia. This stent was also the first stent that did not necessitate the formation of a tracheal stoma [14]. Silicone stents have the advantage of being easily removed and exchanged when needed, and they are relatively inexpensive. This is important in patients who respond to systemic treatment of their disease because their airway can be reevaluated after removal of the silicone stent.
One of the largest studies of silicone stents was published by Dumon and colleagues [15]. In three European centers, 698 patients had silicone stents placed for malignant airway obstruction. Stent migration was reported as the most common complication (9.5%), followed by granulation tissue formation (8%) and mucous plugging (4%).
Wood and colleagues [16] reviewed their single institutional experience with endobronchial stents from 1992 to 2001. Stents were placed in 143 patients for malignant and benign stenoses. Silicone stents with proximal and distal flanges and exterior studs were used in 87% of the patients, and metal stents were used in the other 13%. In addition to stent placement, some patients required other interventions, including rigid bronchoscopy coring-out in 18%, balloon dilation in 11%, brachytherapy in 3%, laser in 3%, and photodynamic therapy in 1%. Stents were placed in 5 patients for compression from mediastinal lymphoma or germ cell tumor. Four of the 5 stents were removed after completion of therapy. The level of difficulty in retrieving the stent was not mentioned. A bronchoscopic procedure was done in 59% of patients, but 21% required two procedures, and 6% required three procedures. Complications occurred in 42% of the procedures, with the most common being retained secretions (27%), followed by granulation tissue formation (9%) and stent migration (5%). No patients died; however, airway perforation was seen in 4 patients, and 1 required an operation. Overall, 95% of the patients reported significant improvement in symptoms.
In contrast to the silicone stents, endobronchial metal stents were less likely to inhibit the respiratory cilia or dislodge. The early generation of endobronchial metal prostheses were developed from endovascular stent technology. The metal is usually steel or nitinol. These stents (Strecker, Palmaz) required a balloon to be placed into the stent, after it was in proper position, so it would expand to meet the walls of the lumen. This cumbersome step was eliminated with the advent of the self-expanding metal stents (SEMS).
The SEMS have become popular endobronchial prostheses owing to the relative ease in placement. These stents are compressed into a small delivery device, and once deployed, a radial force embeds the stent into the surrounding tissue. They can be positioned and deployed with a flexible bronchoscope, which allows some patients to have this placed in an outpatient setting. These stents have the potential for tumor in-growth along the length of the stent. As a result, the uncovered metal stents are used to the most benefit in patients with extraluminal airway compression [17]. The biggest disadvantage of these stents is they are permanent. Once seated and incorporated, they can be difficult if not impossible to remove.
The covered SEMS (Ultraflex and Wallstent, both Boston Scientific/Microvasive, Natick, MA) were developed as a hybrid of silicone and metal stents. They have a decreased risk of tumor in-growth and granulation tissue formation except at the ends, which are kept bare for anchoring to the mucosa. This last feature gives them the shared advantage with their uncovered counterparts of decreased migration compared with silicone stents. They are more easily removable than the uncovered stents; however, granulation tissue in-growth at the ends makes them harder to remove than the pure silicone stents. Several disadvantages of metal stents include their high cost, difficulty moving them once deployed, and the in-growth of granulation tissue that leads to reocclusion of the lumen.
A large, single-institution retrospective review was done by DAmico and colleagues [18]. Of the 172 patients with stent placement between 1997 and 2003, 140 had malignant disease. Contrary to Wood and colleagues, their institutional preference was metal stents. Self-expanding metal stents were placed 166 of 172 patients, and the rigid metal stents were placed in the other 6 patients. Silicone prostheses were not used. No intraoperative deaths were associated with stent placement. Complications occurred in 23 patients, of which the most was tumor in-growth in 9, followed by granulation tissue formation in 7, migration in 5, and external compression leading to restenosis in 2. Stent removal was performed in 5 patients, but the details were not described.
A new advancement in silicone stents was the development of the Polyflex stent (Boston Scientific), which had a thinner wall and could conform better to the airways than its traditional counterparts. The Polyflex stent had problems with migration [19], which was reportedly decreased with the addition of studs on the outer surface [20].
 |
Benign Disease and Stent Placement
|
|---|
In addition to inflammatory disease and long tracheobronchial strictures nonamenable to surgery, stents have been placed in postlung transplantation strictures with a reported 83% immediate improvement of dyspnea after placement [21]. Mughal and associates [22] reported their experience in 7 patients with high-grade anastomotic dehiscence after lung transplantation. They believed the mortality rate from a second operation would be too high, so they choose uncovered SEMs, which allowed drainage of the mediastinum. Two patients died, one from a pulmonary embolism and the other from multiorgan failure. In the other 5 patients, they believe the ingrowth of granulation tissue helped heal the dehiscence. They found the stents could be removed without difficulty 6 to 8 weeks after placement.
The occurrence of obstructing granulation tissue after stenting is reported to be 12% to 28% in patients with benign disease [23–26]. In-stent granulation tissue has been treated successfully with one or more sessions of laser resection or electrocautery [24, 27]. The formation of in-stent granulation tissue requiring multiple treatments has led to the development of retrievable stents that would be removed after treatment was complete.
In performing a systematic review of the literature, we found 7 published reports by Song and colleagues [28–34], who have been investigating a stent and retrieval hook they designed. Their findings across these publications suggest that their nitinol stent is easily removed with minimal to no complications. They have reported its use in benign and malignant disease as well as in tracheoesophageal fistulas. These case series are small and performed in a retrospective manner.
Li and colleagues [35] described the successful use of a Hans stent in the treatment of bronchopleural fistula. The stents were removed in 7 of the 8 patients after successful closure of the bronchopleural fistula without any complications noted. Finally, Noppen and colleagues [36] reported the removal of 10 covered stents. Bleeding and mucosal dehiscence occurred in 20% of the patients, and parts of the wire from the stents were left in 33.3% of the patients.
Publications on retrievable metallic stents are scarce. It has been well documented that the silicone stents are easily removed and exchanged. Many publications report on covered metal stents and their complications, but no large series has described the level of difficulty and complications associated with removal of the covered stents. And to date, no large randomized trial has compared silicone stents and metal stents.
In conclusion, patients with life-threatening airway obstruction secondary to a malignant cause can benefit from endobronchial interventions, which can help return these patients to a significant quality of life [9–11, 37]. Relief of central airway obstruction with an endobronchial prosthesis may result in resolution of a postobstructive pneumonia, which may allow a small percentage of patient to receive chemotherapy not given in the presence of an infection or to undergo a surgical procedure. Relief of a stenosis may provide symptomatic relief that can bridge the patient until further therapy is initiated.
Many advantages as well as disadvantages are associated with each type of endobronchial stent. There is no ideal stent, and no data have shown an absolute benefit of one stent rather than another [38–42]. In patients with benign disease and a reasonable life expectancy, permanent stents are not ideal because of in-stent granulation tissue formation. Retrievable stents are being investigated to help alleviate this problem, but they do not fulfill the requirements of an ideal stent. We need to continue to investigate this technology to allow us to palliate and treat patients whose disease or poor medical condition precludes surgical therapy.
 |
References
|
|---|
- U.S. National Institutes of HealthNational Cancer Institute Lung cancerhttp://www.cancer.gov/cancertopics/types/lungAccessed August 17, 2007.
- Stohr S, Bolliger CT. Stents in the management of malignant airway obstruction Monaldi Arch Chest Dis 1999;54:264-268.[Medline]
- Noppen M, Meysman M, DHaese J. Interventional bronchoscopy: 5-year experience at the Academic Hospital of the Vrije Universiteit Brussel Acta Clin Belg 1997;52:371-380.[Medline]
- Bolliger CT, Soler M, Tamm M. Combination endobronchial and conventional therapy possibilities in inoperable central lung tumors Schweiz Med Wochenschr 1995;125:1052-1059.[Medline]
- Venuta F, Rendina EA, De Giacomo T. Nd:YAG laser resection of lung cancer invading the airway as a bridge to surgery and palliative treatment Ann Thorac Surg 2002;74:995-998.[Abstract/Free Full Text]
- Wood DE. Airway stenting Chest Surg Clin North Am 2001;11:841-860.[Medline]
- Santos RS, Raftopoulus y, Keenan RJ, et al. Bronchoscopic palliation of primary lung cancer: single or multimodality therapy? Surg Endosc 2004;18:931-936.[Medline]
- Stephens KE, Wood DE. Bronchoscopic management of central airway obstruction J Thorac Cardiovasc Surg 2000;119:289-296.[Abstract/Free Full Text]
- Mathisen DJ, Grillo HC. Endoscopic relief of malignant airway obstruction Ann Thorac Surg 1989;48:469-475.[Abstract]
- Sonnett JR, Keenan RJ, Ferson PF, et al. Endobronchial management of benign, malignant, and lung transplantation airway stenosis Ann Thorac Surg 1995;59:1417-1422.[Abstract/Free Full Text]
- Chhajed PN, Baty F, Pless M, et al. Outcome of treated advance non-small cell lung cancer with and without airway obstruction Chest 2006;130:1803-1807.[Medline]
- Meyers BF, de la Morena M, Sweet SC, et al. Primary graft dysfunction and other selected complications of lung transplantation: a single-center experience of 983 patients J Thorac Cardiovasc Surg 2005;129:1421-1429.[Abstract/Free Full Text]
- Montgomery WW. T-tube tracheal stent Arch Otolaryngol 1965;82:320-321.[Abstract/Free Full Text]
- Bolliger CT, Sutedja TG, Strausz J, Freitag L. Therapeutic bronchoscopy with immediate effect: laser, electrocautery, argon plasma coagulation and stents Eur Respir J 2006;27:1258-1271.[Abstract/Free Full Text]
- Dumon JF, Cavaliere S, Diaz-Jiminez JP, et al. Seven-year experience with the Dumon prosthesis J Bronchol 1996;31:6-10.
- Wood DE, Yun-Hen L, Vallieres E, et al. Airway stenting for malignant and benign tracheobronchial stenosis Ann Thorac Surg 2003;76:167-174.[Abstract/Free Full Text]
- Tojo T, Iioka S, Kitamura S, et al. Management of malignant tracheobronchial stenosis with metal stents and Dumon stents Ann Thorac Surg 1996;61:1074-1078.[Abstract/Free Full Text]
- Lemaire A, Burfeind WR, Toloza E, et al. Outcomes of tracheobronchial stents in patients with malignant airway disease Ann Thorac Surg 2005;80:434-438.[Abstract/Free Full Text]
- Gildea TR, Murthy SC, Sahoo D, et al. Performance of a self-expanding silicone stent in palliation of benign airway conditions Chest 2006;130:1419-1423.[Medline]
- Bolliger CT, Breitenbuecher A, Brutsche M, Heitz M, Stanzel F. Use of studded Polyflex stents in patients with neoplastic obstruction of the central airways Respiration 2004;71:83-87.[Medline]
- Saad CP, Ghamande SA, Minai OA, et al. The role of self-expandable metallic stents for the treatment of airway complications after lung transplantation Transplantation 2003;75:1532-1538.[Medline]
- Mughal MM, Gildea TR, Murthy S, et al. Short-term deployment of self-expanding metallic stents facilitates healing of bronchial dehiscence Am J Respir Crit Care Med 2005;172:768-771.[Abstract/Free Full Text]
- Kshettry VR, Kroshus TJ, Hertz MI, Hunter DW, Shumway SJ, Bolman 3rd RM. Early and late airway complications after lung transplantation: incidence and management Ann Thorac Surg 1997;63:1576-1583.[Abstract/Free Full Text]
- Saad CP, Ghamande SA, Minai OA, et al. The role of self-expandable metallic stents for the treatment of airway complications after lung transplantation Transplantation 2003;75:1532-1538.[Medline]
- Rousseau H, Dahan M, Laugue D, et al. Self-expandable protheses in the tracheobronchial tree Radiology 1993;188:199-203.[Abstract/Free Full Text]
- Dasgupta A, Dolmatch BL, Abi-Saleh WJ, Mathur PN, Mehta AC. Self-expandable metallic airway stent insertion employing flexible bronchoscopy: preliminary results Chest 1998;114:106-109.[Medline]
- Saad CP, Murthy S, Krizmanich G, Mehta AC. Self-expandable metallic airway stents and flexible bronchoscopy Chest 2003;124:1993-1999.[Medline]
- Song HY, Shim TS, Kang SG, et al. Tracheobronchial strictures: treatment with a polyurethane-covered retrievable expandable nitinol stent-initial experience Radiology 1999;213:905-912.[Abstract/Free Full Text]
- Shin JH, Kim SW, Shim TS, et al. Malignant tracheobronchial strictures: palliation with covered retrievable expandable nitinol stents J Vasc Interv Radiol 2003;14:1525-1534.[Medline]
- Kim JH, Shin JH, Shim TS, et al. Efficacy and safety of a retrieval hook for removal of retrievable expandable tracheobronchial stents J Vasc Interv Radiol 2004;15:697-705.[Medline]
- Kim JH, Shin JH, Shim TS, et al. Results of temporary placement of covered retrievable expandable nitinol stent for tuberculous bronchial strictures J Vasc Interv Radiol 2004;15:1003-1008.[Medline]
- Nam DH, Shin JH, Song HY, et al. Malignant esophageal-tracheobronchial strictures; parallel placement of covered retrievable expandable nitinol stents Acta Radiol 2006;47:3-9.[Medline]
- Shin JH, Song HY, Ko GY, et al. Treatment of tracheobronchial obstruction with polytetrafluoroethylene-covered retrievable expandable nitinol stent J Vasc Interv Radiol 2006;4:657-663.
- Kim JH, Shin JH, Song HY, Shim TS, Yoon CJ, Ko GY. Benign tracheobronchial strictures: long-term results and factors affecting airway patency after temporary stent placement AJR Am J Roentgenol 2007;188:1033-1038.[Abstract/Free Full Text]
- Li YD, Han XW, Li MH, Wu G. Bronchial stump fistula: treatment with covered, retrievable, expandable, hinged stents- preliminary clinical experience Acta Radiol 2006;47:922-926.[Medline]
- Noppen M, Stratakos G, DHaese J, et al. Removal of covered self-expandable metallic airway stents in benign disorders Chest 2005;127:482-487.[Medline]
- Cavaliere S, Venuta F, Foccoli P, Toninelli C, La Face B. Endoscopic treatment of malignant airway obstructions in 2,008 patients Chest 1996;110:1536-1542.[Medline]
- Stockton PA, Ledson MJ, Hind CR, Walshaw MJ. Bronchoscopic insertion of Gianturco stents for the palliation of malignant lung disease: 10 year experience Lung Cancer 2003;42:113-117.[Medline]
- Bolliger CT, Probst R, Tschopp K, Solèr M, Perruchoud AP. Silicone stents in the management of inoperable tracheobronchial stenosesIndications and limitations. Chest 1993;104:1653-1659.[Medline]
- Bolliger CT, Heitz M, Hauser R, Probst R, Perruchoud AP. An airway Wallstent for the treatment of tracheobronchial malignancies Thorax 1996;51:1127-1129.[Abstract/Free Full Text]
- Miyazawa T, Yamakido M, Ikeda S, et al. Implantation of Ultraflex nitinol stents in malignant tracheobronchial stenoses Chest 2000;118:959-965.[Medline]
- Monnier P, Mudry A, Stanzel F, et al. The use of the covered Wallstent for the palliative treatment of inoperable tracheobronchial cancersA prospective, multicenter study. Chest 1996;110:1161-1168.[Medline]
This article has been cited by other articles:

|
 |

|
 |
 
S. Bahrami, D. Chow, and B. Kadell
Thoracic and Abdominal Devices Radiologists Should Recognize: Pictorial Review
Am. J. Roentgenol.,
December 1, 2009;
193(6_Supplement):
S106 - S118.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Bahrami, D. Chow, and B. Kadell
Thoracic and Abdominal Devices Radiologists Should Recognize: Self-Assessment Module
Am. J. Roentgenol.,
December 1, 2009;
193(6_Supplement):
S119 - S122.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H.-S. Nam, S. W. Um, W.-J. Koh, G. Y. Suh, M. P. Chung, O. J. Kwon, J. Kim, and H. Kim
Clinical application of the Natural Y stent in the management of benign carinal stenosis.
Ann. Thorac. Surg.,
August 1, 2009;
88(2):
432 - 439.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. H. Kim, J. H. Shin, H.-Y. Song, J.-Y. Ohm, J. M. Lee, D. H. Lee, and S.-W. Kim
Palliative Treatment of Inoperable Malignant Tracheobronchial Obstruction: Temporary Stenting Combined With Radiation Therapy and/or Chemotherapy
Am. J. Roentgenol.,
July 1, 2009;
193(1):
W38 - W42.
[Abstract]
[Full Text]
[PDF]
|
 |
|